Discontinued — last reported Q4 '24
Business Segments · Goodwill, Impairment Loss
Biopharma Laboratory Services — Goodwill, Impairment Loss
Year-over-year, this metric declined by 100.0%, from $83.40M to $0.00. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryCapital Allocation
SignalLower is better
VolatilityVolatile
First reportedQ1 2023
Last reportedQ4 2024
Rolls up toGoodwill impairment
How to read this metric
An impairment loss signals that the segment's long-term growth prospects or profitability have weakened compared to initial acquisition assumptions.
Detailed definition
This metric quantifies the reduction in the carrying value of goodwill specifically attributed to the Biopharma Laborato...
Peer comparison
Standard accounting metric for 'Goodwill Impairment' found in the financial statements of any company that has engaged in M&A activity.
Metric ID:
lh_segment_biopharma_laboratory_services_goodwill_impairment_lossHistorical Data
2 years
| FY'23 | FY'24 | |
|---|---|---|
| Value | $333.60M | $0.00 |
| YoY Change | — | -100.0% |
Range$0.00 – $333.60M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's biopharma laboratory services — goodwill, impairment loss?
- Labcorp Holdings (LH) reported biopharma laboratory services — goodwill, impairment loss of $0.00 in Q4 2024.
- How has Labcorp Holdings's biopharma laboratory services — goodwill, impairment loss changed year-over-year?
- Labcorp Holdings's biopharma laboratory services — goodwill, impairment loss decreased by 100.0% year-over-year, from $83.40M to $0.00.
- What does biopharma laboratory services — goodwill, impairment loss mean?
- A non-cash charge taken when the value of a previously acquired business unit is determined to be lower than its recorded value.